NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
22 hedge funds and large institutions have $340K invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more capital invested
Capital invested by funds: $301K → $340K (+$39K)
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$47.9K |
| 2 |
Renaissance Technologies
New York
|
+$41.6K |
| 3 |
Two Sigma Investments
New York
|
+$15.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$10.7K |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$1.09K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$264 |
| 4 |
BlackRock
New York
|
-$260 |
| 5 |
First Manhattan
New York
|
-$257 |
NBSE Hedge Fund Activity: Q4 2023 in Review
22 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2023, worth a combined $340K — up 13% from $301K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NBSE positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $47.9K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $10.7K sold.
- 22 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $340K of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2023, up 13% quarter-over-quarter.
- 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of +2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2023 was UBS Group, an estimated $47.9K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2023 was Two Sigma Securities, an estimated $10.7K sold.
Based on aggregated 13F filings for Q4 2023.